RC
SGMO

RegentAtlantic Capital’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

RegentAtlantic Capital’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-500
Closed -$7.61K – 836
2014
Q4 		$7.61K Buy
+500
New +$6.07K ﹤0.01% 949

Other funds holding SGMO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

RegentAtlantic Capital's SGMO Position: Q1 2015 in Review

RegentAtlantic Capital sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q1 2015, closing a stake of 500 shares — an estimated $7.61K sold.

RegentAtlantic Capital first reported a position in SGMO in Q4 2014 and held it in 1 quarter. The position peaked at $7.61K in Q4 2014. 171 funds tracked by Wall St. Rank hold SGMO as of Q1 2015.

  • RegentAtlantic Capital reported no remaining SANGAMO THERAPEUTICS INC position as of Q1 2015 after selling out during the quarter.
  • RegentAtlantic Capital sold 500 SANGAMO THERAPEUTICS INC shares in Q1 2015, an estimated $7.61K.
  • RegentAtlantic Capital first reported a position in SANGAMO THERAPEUTICS INC in Q4 2014 and held it in 1 quarter.
  • RegentAtlantic Capital's SANGAMO THERAPEUTICS INC position peaked at $7.61K in Q4 2014.
  • 171 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2015.

Based on RegentAtlantic Capital's 13F filing for Q1 2015, filed 27 Apr 2015.